Oqory

Executive Summary

Oqory is a clinical-stage biotechnology company headquartered in Boston, focused on developing next-generation antibody-drug conjugates (ADCs) for oncological indications. Founded in 2021, the company has built a proprietary ADC discovery and development platform that enables precise targeting of tumor antigens while minimizing off-target toxicity. Oqory's pipeline includes multiple clinical candidates currently in Phase 1 studies, addressing a range of solid tumors. The company's platform leverages novel linker-payload technologies and optimized antibody engineering to enhance therapeutic index. With a robust preclinical pipeline and early clinical validation, Oqory aims to address significant unmet needs in oncology, particularly in indications where conventional ADCs have shown limited efficacy or tolerability. The company is privately held and has not disclosed financial details, but its progress in advancing candidates through the clinic positions it as a potential player in the competitive ADC landscape.

Upcoming Catalysts (preview)

• Q1 2027Phase 1 interim data readout for lead ADC candidate60% success
• Q3 2026IND filing for second pipeline candidate70% success
• Q4 2026Potential partnership or licensing deal for platform technology40% success